Neuropeutics
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A private biotech leveraging proprietary TDP‑43 targeting to develop disease‑modifying therapies for neurodegenerative disorders.
Neurodegenerative Diseases
Technology Platform
Proprietary cellular and animal models targeting TDP‑43 aggregation, with a small‑molecule (JRMS‑22) that leverages a non‑canonical function of an undisclosed protein to reverse toxic protein aggregation.
Opportunities
First‑in‑class TDP‑43 aggregation reversal could address a major unmet need across multiple neurodegenerative diseases, offering platform potential for expansion beyond ALS.
Risk Factors
Preclinical data may not translate to human efficacy; substantial funding required for IND and clinical trials; competition from larger firms with alternative modalities.
Competitive Landscape
Competes with biotech and pharma firms developing ALS and neurodegeneration therapies (e.g., Biogen, Roche), but differentiates by directly targeting TDP‑43 pathology, a novel upstream mechanism.